Microchip Technology vs STMicroelectronics
MCHP and STM side by side, both in electronic components and accessories. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MCHP and STM compare
Microchip Technology grew revenue faster over the last twelve months (20.9% versus −11.1% for STMicroelectronics).
Microchip Technology keeps more of each dollar of sales as profit, with a net margin of 9.3% compared with 1.4% at STMicroelectronics.
Microchip Technology pays a dividend yielding 2.4%; STMicroelectronics does not pay one.
Microchip Technology scores higher on the StockData Score (12 against 4 for STMicroelectronics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MCHP | STM |
|---|---|---|
| Size and price | ||
| Market cap | $42.0B | – |
| Share price | $77.34 | $46.74 |
| Change, 1 year | 23.7% | 89.4% |
| Change, 5 years | −9.8% | −7.9% |
| Beta (5Y) | 1.67 | 1.52 |
| Employees | 18K | 49K |
| StockData Score | ||
| Total score | 12 (better) | 4 |
| Valuation score | 0 | 0 |
| Growth score | 3 (better) | 0 |
| Performance score | 2 (better) | 0 |
| Health score | 4 | 4 |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 115× | – |
| P/S | 8.2× | – |
| P/B | 6.5× | – |
| EV/EBITDA | 32.0× | – |
| P/FCF | 37.8× | – |
| FCF yield | 2.6% | – |
| Fair value | $33.00 | – |
| Margin of safety | −134% | – |
| Growth | ||
| Revenue growth (TTM) | 20.9% (better) | −11.1% |
| Revenue growth, 5Y average | −2.8% | 2.9% (better) |
| Net income growth (TTM) | – | −89.3% |
| EPS growth (TTM) | – | −89.2% |
| EPS growth, 5Y average | −19.5% (better) | −31.6% |
| Profitability | ||
| Gross margin | 60.2% (better) | 33.9% |
| Operating margin | 15.5% (better) | 1.5% |
| Net margin | 9.3% (better) | 1.4% |
| FCF margin | 21.7% | – |
| Return on equity | 7.2% (better) | 0.94% |
| Return on invested capital | 5.6% (better) | 0.55% |
| Financial health | ||
| Debt / equity | 0.83 | 0.12 (better) |
| Net debt / EBITDA | 3.46 (better) | −0.83 |
| Interest coverage | 3.7× (better) | 3.2× |
| Current ratio | 1.92 | 3.36 (better) |
| Altman Z-score | 4.28 | – |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Dividend yield | 2.4% | – |
| Payout ratio | 206% | 193% |
| Years of dividend growth | 17 (better) | 0 |
| Dividend growth, 5Y average | 19.5% | – |
| Buyback yield | −0.15% | – |
| Shareholder yield | 2.2% | – |
| Ownership | ||
| Held by institutions | 100% | 19.1% |
| Held by insiders | 2.0% | 0.00% |
| Insider net buying, 12 months | −$71.1M | – |
| Superinvestors holding | 2 | 3 (better) |
Go deeper
- MCHP stock overview
- MCHP income statement
- MCHP valuation and score
- STM stock overview
- STM income statement
- STM valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.